Introduction: Oxaliplatin, a second-generation platinum analog, has evolved as one of the
most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major …

Oxaliplatin is the only third-generation platinum derivative compound that has found a place
in the routine treatment of colorectal cancer (CRC). The appearance of oxaliplatin, as well as …

Oxaliplatin, the first available diaminocyclohexane platinum, has clinical activity in colorectal
and ovarian cancers. Its mechanism of action is thought to be similar to that of cisplatin, its …

Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing
intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity …

For nearly 40 years, the medical treatment of colorectal cancer had been limited to the
fluoropyrimidines until the recent development of irinotecan (CPT-11). In the past decade, a …

Of the new generation platinum compounds that have been evaluated, those with the 1, 2-
diaminocyclohexane carrier ligand–including oxaliplatin–have been focused upon in recent …

Oxaliplatin (Eloxatin; Sanofi, Gentilly, France), a third-generation platinum compound with a
1, 2-diaminocyclohexane (DACH) carrier ligand, is a recently developed agent with activity …

Oxaliplatin (Eloxatin™), a recently developed third-generation cisplatin analogue with a 1, 2-
diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in …

Oxaliplatin is a novel platinum analogue which has wide spectrum anti‐cancer activity in in
vitro systems. It has distinct biochemical, pharmacological and cytotoxic properties which are …

Novel platinum compounds have been sought with the goal of identifying molecules active
in cisplatin-resistant cancers such as colorectal cancer. Some 30 years ago it was shown …